Search

Nicholas S Kallan

from Merrimack, NH
Get Report
Also known as:
Nicholas C Kallan, N Kallan
Phone and address:
21 Danbury Dr, Merrimack, NH 03054
(603) 424-3925
Connected to:
Daron M Kallan, 52Ronald Kallan, 74Edita A Kalland, 82Tricia A Kalland, 53Jacques G Kallanian, 54Jean-Pierre A Kallanian, 51Donald W Kallansrud, 78Christopher S Kallaos, 45John P Kallaos, 52Lalan Kallarakal, 78

Nicholas Kallan Phones & Addresses

  • 21 Danbury Dr, Merrimack, NH 03054 (603) 424-3925
  • Louisville, CO
  • Boulder, CO
  • Nashua, NH

Business Records

Name / Title
Company / Classification
Phones & Addresses
Nicholas Kallan
President
Ahepa 35, Inc
Services, Nec, Nsk
681 W Hollis St, Nashua, NH 03062

Publications

Us Patents

Hydroxylated And Methoxylated Pyrimidyl Cyclopentanes As Akt Protein Kinase Inhibitors

View page
US Patent:
8063050, Nov 22, 2011
Filed:
Jul 5, 2007
Appl. No.:
11/773949
Inventors:
Ian S. Mitchell - Lafayette CO, US
James F. Blake - Longmont CO, US
Rui Xu - Longmont CO, US
Nicholas C. Kallan - Boulder CO, US
Dengming Xiao - Longmont CO, US
Keith Lee Spencer - Lyons CO, US
Josef R. Bencsik - Longmont CO, US
Eli M. Wallace - Lyons CO, US
Stephen T. Schlachter - Boulder CO, US
Anna L. Banka - Longmont CO, US
Jun Liang - Palo Alto CA, US
Brian Safina - Redwood City CA, US
Birong Zhang - Union City CA, US
Christine Chabot - San Mateo CA, US
Steven Do - San Jose CA, US
Assignee:
Array BioPharma Inc. - Boulder CO
Covenentech, Inc. - South San Francisco CA
International Classification:
C07D 239/70
A61K 31/496
A61P 35/00
US Classification:
51425216, 544253
Abstract:
The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I:Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Imidazo[1,2-A]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors

View page
US Patent:
8138181, Mar 20, 2012
Filed:
Mar 27, 2008
Appl. No.:
12/593879
Inventors:
Shelley Allen - Loveland CO, US
Julie Marie Greschuk - Erie CO, US
Nicholas C. Kallan - Boulder CO, US
Mark C. Munson - Louisville CO, US
James P. Rizzi - Longmont CO, US
John E. Robinson - Commerce City CO, US
Stephen T. Schlachter - Boulder CO, US
George T. Topalov - Superior CO, US
Qian Zhao - Superior CO, US
Joseph P. Lyssikatos - Piedmont CA, US
Assignee:
Array BioPharma Inc. - Boulder CO
International Classification:
A61K 31/5386
A61K 31/437
A61K 31/506
C07D 471/02
C07D 401/14
C07D 498/08
A61P 35/04
US Classification:
5142305, 514300, 514256, 546121, 544333, 544105
Abstract:
Compounds of Formula I: in which A, B, R, R, R, R, R, RR, Rand Rhave the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.

Dihydrofuro Pyrimidines As Akt Protein Kinase Inhibitors

View page
US Patent:
8329701, Dec 11, 2012
Filed:
Jul 5, 2007
Appl. No.:
12/307537
Inventors:
Ian S. Mitchell - Lafayette CO, US
James F. Blake - Longmont CO, US
Rui Xu - Longmont CO, US
Nicholas C. Kallan - Boulder CO, US
Dengming Xiao - Longmont CO, US
Keith Lee Spencer - Lyons CO, US
Josef R. Bencsik - Longmont CO, US
Assignee:
Array Biopharma Inc. - Boulder CO
International Classification:
A61K 31/519
A61P 29/00
A61P 17/00
A61P 9/00
A61P 25/28
A61P 15/00
A61P 35/00
C07D 491/048
US Classification:
51425216, 544278
Abstract:
The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

5H-Cyclopenta[D]Pyrimidines As Akt Protein Kinase Inhibitors

View page
US Patent:
8329709, Dec 11, 2012
Filed:
Jan 9, 2009
Appl. No.:
12/812377
Inventors:
Anna L. Banka - Boulder CO, US
Josef R. Bencsik - Boulder CO, US
James Blake - Boulder CO, US
Martin Hentemann - Boulder CO, US
Nicholas C. Kallan - Boulder CO, US
Jun Liang - South San Francisco CA, US
Ian S. Mitchell - Boulder CO, US
Stephen T. Schlachter - Boulder CO, US
Eli M. Wallace - Boulder CO, US
Rui Xu - Boulder CO, US
Tony P. Tang - Boulder CO, US
Assignee:
Genentech, Inc. - South San Francisco CA
Array BioPharma Inc. - Boulder CO
International Classification:
A61K 31/517
C07D 239/70
US Classification:
5142581, 544253
Abstract:
Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

Pyrimidyl Cyclopentanes As Akt Protein Kinase Inhibitors

View page
US Patent:
8377937, Feb 19, 2013
Filed:
Jul 3, 2008
Appl. No.:
12/667850
Inventors:
Josef R. Bencsik - Longmont CO, US
James F. Blake - Longmont CO, US
Nicholas C. Kallan - Boulder CO, US
Ian S. Mitchell - Lafayette CO, US
Keith L. Spencer - Lyons CO, US
Dengming Xiao - Longmont CO, US
Rui Xu - Longmont CO, US
Christine Chabot - Menlo Park CA, US
Jun Liang - Palo Alto CA, US
Brian S. Safina - Redwood City CA, US
Assignee:
Array BioPharma Inc. - Boulder CO
Genentech, Inc. - South San Francisco CA
International Classification:
C07D 239/70
A61K 31/517
US Classification:
51425216, 544253
Abstract:
The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Triazolopyridine Compounds As Pim Kinase Inhibitors

View page
US Patent:
8575145, Nov 5, 2013
Filed:
Aug 18, 2009
Appl. No.:
13/059902
Inventors:
Shelley Allen - Boulder CO, US
Laura L. Celeste - Gaithersburg MD, US
T. Gregg Davis - Boulder CO, US
Robert Kirk DeLisle - Boulder CO, US
Julie Marie Greschuk - Boulder CO, US
Stefan D. Gross - Superior CO, US
Erik James Hicken - Boulder CO, US
Leila J. Jackson - Boulder CO, US
Nicholas C. Kallan - Boulder CO, US
Joseph P. Lyssikatos - Piedmont CO, US
Fredrik P. Marmsater - Boulder CO, US
Mark C. Munson - Boulder CO, US
Jed Pheneger - Boulder CO, US
Bryson Rast - Westminster CO, US
John E. Robinson - Boulder CO, US
Stephen T. Schlachter - Boulder CO, US
George T. Topalov - Boulder CO, US
A. Dale Wright - Boulder CO, US
Qian Zhao - Boulder CO, US
Assignee:
Array BioPharma Inc. - Boulder CO
International Classification:
A61K 31/55
A61K 31/437
A61K 31/513
A61K 31/5377
C07D 471/04
A61P 35/00
A61P 25/00
A61P 29/00
US Classification:
51421021, 514303, 51421707, 514272, 5142332, 546119, 544331, 544127, 540597
Abstract:
Compounds of Formula (I), in which A, B, R, R, R, R, R, R, R, and Rhave the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.

Pyrimidyl Cyclopentanes As Akt Protein Kinase Inhibitors

View page
US Patent:
8618097, Dec 31, 2013
Filed:
Jul 3, 2008
Appl. No.:
12/667848
Inventors:
Josef Bencsik - Longmont CO, US
James F. Blake - Longmont CO, US
James M. Graham - Longmont CO, US
Martin F. Hentemann - Lafayette CO, US
Nicholas C. Kallan - Boulder CO, US
Ian S. Mitchell - Lafayette CO, US
Stephen T. Schlachter - Boulder CO, US
Keith L. Spencer - Lyons CO, US
Dengming Xiao - Longmont CO, US
Rui Xu - Longmont CO, US
Mike Welch - Westminster CO, US
Jun Liang - Palo Alto CA, US
Brian S. Safina - Redwood City CA, US
Assignee:
Array Biopharma, Inc. - Boulder CO
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 31/5377
A61K 31/496
C07D 413/14
C07D 239/70
A61P 25/28
A61P 35/00
A61P 29/00
A61P 9/00
US Classification:
5142345, 51425215, 51425216, 544121, 544230, 544253
Abstract:
The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Akt Protein Kinase Inhibitors

View page
US Patent:
20050130954, Jun 16, 2005
Filed:
Nov 19, 2004
Appl. No.:
10/993173
Inventors:
Ian Mitchell - Lafayette CO, US
Keith Spencer - Lyons CO, US
Peter Stengel - Longmont CO, US
Yongxin Han - Longmont CO, US
Nicholas Kallan - Boulder CO, US
Mark Munson - Louisville CO, US
Guy Vigers - Boulder CO, US
James Blake - Longmont CO, US
Anthony Piscopio - Longmont CO, US
John Josey - Longmont CO, US
Scott Miller - Longmont CO, US
Dengming Xiao - Longmont CO, US
Riu Xu - Longmont CO, US
Chang Rao - Waltham MA, US
Bin Wang - Longmont CO, US
April Bernacki - Longmont CO, US
International Classification:
A61K031/53
A61K031/519
A61K031/496
US Classification:
514210210, 514264100, 514256000, 514249000, 514248000, 514266200, 514246000, 514314000, 514252160, 514253060, 544279000, 544182000, 544284000, 544363000, 546122000, 546117000, 514300000
Abstract:
The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Control profile
Nicholas S Kallan from Merrimack, NH Get Report